Please check your internet connection and try again.
# Urimax (tamsulosin)
## Overview
- Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in prostate and bladder neck.
- Not indicated for hypertension (unlike non-selective alpha blockers).
## Primary Indications
- Signs and symptoms of benign prostatic hyperplasia (BPH).
- Off-label: medical expulsive therapy for distal ureteral stones (limited evidence; pediatric use not well-established).
## Adult Dosing
- **Initial:** 0.4 mg orally once daily, approximately 30 minutes after the same meal each day.
- **If inadequate response after 2–4 weeks:** may increase to 0.8 mg once daily. Maximum dose: 0.8 mg/day.
- Capsules must be swallowed whole; do not crush, chew, or open.
## Pediatric Dosing
- No FDA-approved pediatric indication.
- **Off-label for ureteral stones:** Limited data; typical doses range 0.2–0.4 mg once daily in children ≥6 years (exact dosing depends on institutional protocol and weight). Safety and efficacy not established.
## Dose Adjustments
- **Renal impairment:** No adjustment for mild-moderate (CrCl ≥10 mL/min). Insufficient data for severe impairment (CrCl <10 mL/min) – use caution.
- **Hepatic impairment:** Contraindicated in severe impairment. Use caution in moderate impairment; no specific dose adjustment defined.
- **Elderly:** Start at 0.4 mg daily; no routine dose adjustment.
## Contraindications
- Hypersensitivity to tamsulosin or any component.
- History of orthostatic hypotension or micturition syncope.
- Severe hepatic insufficiency (Child-Pugh class C).
## Adverse Effects
- **Common:** dizziness, rhinitis, abnormal ejaculation (retrograde or decreased volume), headache, asthenia.
- **Serious:** orthostatic hypotension (especially first dose), syncope, intraoperative floppy iris syndrome (IFIS) during cataract surgery, priapism (rare).
- **Other:** somnolence, blurred vision, nasal congestion.
## Key Drug Interactions
- **Other alpha-adrenergic blockers** (e.g., prazosin, doxazosin): additive hypotension – avoid combination.
- **Antihypertensives** (especially diuretics, beta-blockers, calcium channel blockers): enhanced hypotensive effect.
- **PDE5 inhibitors** (sildenafil, tadalafil, vardenafil): increased risk of hypotension; use lowest doses and separate administration times.
- **CYP3A4 inhibitors** (e.g., ketoconazole, ritonavir) and **CYP2D6 inhibitors** (e.g., paroxetine): may increase tamsulosin exposure; consider dose reduction or monitoring.
- **Warfarin:** no significant interaction reported; monitor INR if co-administered.
## Monitoring
- Symptoms of BPH (IPSS score, flow rate, post-void residual).
- Blood pressure (supine and standing) at initiation and after dose increase.
- PSA levels: Tamsulosin does not affect PSA; maintain routine screening.
- During cataract surgery: inform ophthalmologist of tamsulosin use (risk of IFIS).
## Clinical Pearls
- **First-dose orthostatic hypotension:** Instruct patient to take at bedtime initially to reduce fall risk; avoid driving until response known.
- **Administer with same meal daily** to ensure consistent absorption and efficacy.
- **Do not open capsules:** contents may cause throat irritation.
- **If surgery planned** (especially cataract), document alpha-blocker history; IFIS risk persists even after discontinuation.
- **Reassess need for continued therapy** after 3–6 months; may consider reducing dose if symptoms controlled.
---
*Educational disclaimer: This information is for educational purposes and does not replace clinical judgment. Always consult current prescribing information, local protocols, and the drug manufacturer’s labeling before initiating therapy.*
